Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

FDA Authorizes COVID-19 Vaccine Boosters for Immunocompromised Individuals

FDA Authorizes COVID-19 Vaccine Boosters for Immunocompromised Individuals

FromXtalks Life Science Podcast


FDA Authorizes COVID-19 Vaccine Boosters for Immunocompromised Individuals

FromXtalks Life Science Podcast

ratings:
Length:
29 minutes
Released:
Aug 18, 2021
Format:
Podcast episode

Description

In this episode, Ayesha discussed the US Food and Drug Administration’s (FDA) authorization of a third dose of the Pfizer and Moderna COVID-19 vaccines for immunocompromised individuals. These individuals would primarily include organ transplant recipients, as well as patients taking immunosuppressive drugs for conditions like cancer and HIV/AIDS. Many people with weakened immune systems have been shown to have either low antibody titers, or none at all, after receiving a standard two-dose regimen of the Pfizer and Moderna COVID-19 vaccines. The FDA said additional vaccine doses for the general public are currently unwarranted. The editorial team discussed whether COVID-19 vaccine boosters could become a norm depending on how the SARS-CoV-2 virus, and the pandemic it has caused, evolves.FDA Authorizes COVID-19 Vaccine Boosters for Immunocompromised IndividualsFor more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured
Released:
Aug 18, 2021
Format:
Podcast episode

Titles in the series (100)

This Life Science focused podcast brings together Xtalks editorial staff to share insights into the latest B2B industry news. Xtalks connects professionals in the life science, medical device, and food industries with useful content like webinars, job opening, articles and virtual meetings.